FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118370710> ?p ?o ?g. }

• W2118370710 endingPage "58" @default.
• W2118370710 startingPage "50" @default.
• W2118370710 abstract "ObjectivesPegylated-interferon-α (IFN-α)-based therapies for viral hepatitis C (HCV) are effective, but they are associated with several adverse events (AEs). The primary objectives of this study were to quantify the burden of IFN-α–based treatment and to measure the prevalence and burden of IFN-α–related AEs in Japan.MethodsA cross-sectional survey was administered online to patients with HCV in 2013. Patients who were currently taking IFN-α–based therapy (n = 188) were compared with patients who were taking a liver protectant but not IFN-α–based therapy (n = 180) and with patients who were untreated (n = 365) on measures of health-related quality of life (using the Hepatitis Quality of Life Questionnaire, version 2), work productivity, and health care resource use, controlling for sociodemographic characteristics and health history. Among patients taking IFN-α–based therapy, the prevalence and burden of AEs was examined on the same set of health outcomes as noted above along with treatment satisfaction and adherence.ResultsCompared with untreated patients, patients using IFN-α reported poorer health-related quality of life (physical component summary score, 50.13 vs. 52.04; mental component summary score, 44.12 vs. 47.97), more overall work impairment (32.73 vs. 25.64), more physician visits in the past 6 months (14.51 vs. 8.36), and an increased likelihood of an emergency room visit (odds ratio = 7.25) and hospitalization (odds ratio = 4.05) (all P < 0.05). The mean number of AEs was 6.05 for patients using IFN-α. All AEs were associated with poorer health outcomes (particularly the mental component summary score), and most were also associated with lower treatment satisfaction and medication adherence.ConclusionsA significant patient burden for IFN-α treatment itself and various AEs was observed. The results suggest that effective, non-IFN-α–based treatments may reduce the societal burden." @default.
• W2118370710 created "2016-06-24" @default.
• W2118370710 creator A5008264667 @default.
• W2118370710 creator A5010376603 @default.
• W2118370710 creator A5023958825 @default.
• W2118370710 creator A5028288918 @default.
• W2118370710 creator A5044932403 @default.
• W2118370710 creator A5046470318 @default.
• W2118370710 creator A5048204415 @default.
• W2118370710 creator A5054619542 @default.
• W2118370710 creator A5057623083 @default.
• W2118370710 creator A5067486160 @default.
• W2118370710 date "2014-05-01" @default.
• W2118370710 modified "2023-10-16" @default.
• W2118370710 title "The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan" @default.
• W2118370710 cites W1482709825 @default.
• W2118370710 cites W1553379116 @default.
• W2118370710 cites W1891664461 @default.
• W2118370710 cites W1966242613 @default.
• W2118370710 cites W1970615440 @default.
• W2118370710 cites W1981496642 @default.
• W2118370710 cites W1988366031 @default.
• W2118370710 cites W2000445173 @default.
• W2118370710 cites W2011235168 @default.
• W2118370710 cites W2011858350 @default.
• W2118370710 cites W2027545702 @default.
• W2118370710 cites W2027865326 @default.
• W2118370710 cites W2045934614 @default.
• W2118370710 cites W2046576867 @default.
• W2118370710 cites W2049695669 @default.
• W2118370710 cites W2050629679 @default.
• W2118370710 cites W2061799663 @default.
• W2118370710 cites W2064551064 @default.
• W2118370710 cites W2066274543 @default.
• W2118370710 cites W2072160870 @default.
• W2118370710 cites W2072939862 @default.
• W2118370710 cites W2086325363 @default.
• W2118370710 cites W2088732481 @default.
• W2118370710 cites W2106791445 @default.
• W2118370710 cites W2107713887 @default.
• W2118370710 cites W2119156880 @default.
• W2118370710 cites W2119844106 @default.
• W2118370710 cites W2126717110 @default.
• W2118370710 cites W2144317224 @default.
• W2118370710 cites W2165715544 @default.
• W2118370710 cites W2204992719 @default.
• W2118370710 cites W2317554121 @default.
• W2118370710 cites W2321732812 @default.
• W2118370710 cites W2341829866 @default.
• W2118370710 cites W3126246200 @default.
• W2118370710 cites W3151592669 @default.
• W2118370710 cites W77457390 @default.
• W2118370710 doi "https://doi.org/10.1016/j.vhri.2014.01.002" @default.
• W2118370710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29702938" @default.
• W2118370710 hasPublicationYear "2014" @default.
• W2118370710 type Work @default.
• W2118370710 sameAs 2118370710 @default.
• W2118370710 citedByCount "3" @default.
• W2118370710 countsByYear W21183707102014 @default.
• W2118370710 countsByYear W21183707102016 @default.
• W2118370710 countsByYear W21183707102019 @default.
• W2118370710 crossrefType "journal-article" @default.
• W2118370710 hasAuthorship W2118370710A5008264667 @default.
• W2118370710 hasAuthorship W2118370710A5010376603 @default.
• W2118370710 hasAuthorship W2118370710A5023958825 @default.
• W2118370710 hasAuthorship W2118370710A5028288918 @default.
• W2118370710 hasAuthorship W2118370710A5044932403 @default.
• W2118370710 hasAuthorship W2118370710A5046470318 @default.
• W2118370710 hasAuthorship W2118370710A5048204415 @default.
• W2118370710 hasAuthorship W2118370710A5054619542 @default.
• W2118370710 hasAuthorship W2118370710A5057623083 @default.
• W2118370710 hasAuthorship W2118370710A5067486160 @default.
• W2118370710 hasBestOaLocation W21183707101 @default.
• W2118370710 hasConcept C118552586 @default.
• W2118370710 hasConcept C126322002 @default.
• W2118370710 hasConcept C134362201 @default.
• W2118370710 hasConcept C156957248 @default.
• W2118370710 hasConcept C159110408 @default.
• W2118370710 hasConcept C197934379 @default.
• W2118370710 hasConcept C203014093 @default.
• W2118370710 hasConcept C2522874641 @default.
• W2118370710 hasConcept C2776408679 @default.
• W2118370710 hasConcept C2776455275 @default.
• W2118370710 hasConcept C2776461080 @default.
• W2118370710 hasConcept C2779951463 @default.
• W2118370710 hasConcept C2780040827 @default.
• W2118370710 hasConcept C71924100 @default.
• W2118370710 hasConceptScore W2118370710C118552586 @default.
• W2118370710 hasConceptScore W2118370710C126322002 @default.
• W2118370710 hasConceptScore W2118370710C134362201 @default.
• W2118370710 hasConceptScore W2118370710C156957248 @default.
• W2118370710 hasConceptScore W2118370710C159110408 @default.
• W2118370710 hasConceptScore W2118370710C197934379 @default.
• W2118370710 hasConceptScore W2118370710C203014093 @default.
• W2118370710 hasConceptScore W2118370710C2522874641 @default.
• W2118370710 hasConceptScore W2118370710C2776408679 @default.
• W2118370710 hasConceptScore W2118370710C2776455275 @default.
• W2118370710 hasConceptScore W2118370710C2776461080 @default.

• next